54
Participants
Start Date
May 31, 2012
Primary Completion Date
July 25, 2018
Study Completion Date
July 25, 2018
MLN8237
Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.
Irinotecan
Irinotecan will be administered intravenously during each course on study day 1 through day 5.
Temozolomide
Temozolomide will be administered orally during each course on study day 1 through day 5.
Children's Healthcare of Atlanta, Atlanta
University of Michigan Comprehensive Cancer Center, Ann Arbor
University of Chicago Comer Children's Hospital, Chicago
Cook Children's Medical Center - Fort Worth, Fort Worth
Children Hospital of Colorado, Aurora
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto
Children's Hospital and Regional Medical Center - Seattle, Seattle
Children's Hospital Los Angeles, Los Angeles
Childrens Hospital Boston, Dana-Farber Cancer Institute., Boston
Cincinnati Children's Hospital Medical Center, Cincinnati
Children's Hospital of Philadelphia, Philadelphia
Hospital for Sick Children, Toronto
New Approaches to Neuroblastoma Therapy Consortium
OTHER